Menstrual and Reproductive Factors in Association With Breast Cancer Risk in Vietnamese Women: A Case-Control Study

Cancer Control Volume 29: 1–10 © The Author(s) 2022 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/10732748221140206 journals.sagepub.com/home/ccx SAGE

Oanh Thi Bui¹, Huong Thanh Tran^{1,2}, Sang Minh Nguyen³, Tu Van Dao^{1,2}, Quang Vinh Bui⁴, Anh Tuan Pham^{1,2}, Martha J. Shrubsole³, Qiuyin Cai³, Fei Ye⁵, Wei Zheng³, Hung Nguyen Luu⁶, Thuan Van Tran^{1,7}, and Xiao-Ou Shu³

Abstract

Objectives: Though menstrual and reproductive factors have been associated with the risk of breast cancer in many populations, very few studies have been conducted among Vietnamese women. This study aimed to assess the association between menstrual and reproductive factors and the risk of breast cancer in Vietnamese women.

Methods: A retrospective case-control study of 490 breast cancer cases and 468 controls was conducted in Northern Vietnam. Unconditional logistic regression models adjusting for confounders were used to estimate odds ratios (ORs) and their 95% confidence intervals (Cls) for the associations of menstrual and reproductive factors with the risk of breast cancer; overall and by cancer subtype.

Results: Among breast cancer patients, the luminal B subtype was the most frequent (48.6%), followed by HER2overexpressing (24.5%), luminal A (16.7%), and triple-negative breast cancer (TNBC; 10.2%). Among menopausal women, menopausal age at 50 years or older (OR = 1.71, 95% CI: 1.15-2.57 vs. <50 y) was associated with an increased risk of breast cancer. Earlier age at menarche (<13 y) was associated with a significantly increased risk of breast cancer (OR = 2.66, 95% CI: 1.08-7.51) among premenopausal women only and the luminal A subtype of breast cancer (OR = 3.06, 95% CI: 1.04-8.16). Having more than two children was associated with a reduced risk of premenopausal (OR = .42, 95% CI: .21-.83), luminal B (OR = .43, 95% CI: .24-.79), and TNBC (OR = .34, 95% CI: .14-.89). Later menopause was positively associated with the risk of breast cancer with HER2 overexpression (OR = 2.19, 95% CI: 1.14-4.23).

Conclusion: Associations of menstrual and reproductive factors with breast cancer among Vietnamese women, particularly for among premenopausal women and for the luminal A subtype, are generally consistent with those reported from other countries. These findings suggest that changes in menstrual and reproductive patterns among young Vietnamese women may contribute to the recent rising incidence of breast cancer in Vietnam.

Corresponding Author:

Huong Thanh Tran, Vietnam National Cancer Institute and Hanoi Medical University, I Ton That Tung Street, Dong Da, Hanoi, Vietnam. Email: huongtran2008@gmail.com



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and

Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

¹Vietnam National Cancer Institute, National Cancer Hospital, Hanoi, Vietnam

²Hanoi Medical University, Hanoi, Vietnam

³Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA

⁴Hanoi Oncology Hospital, Hanoi, Vietnam

⁵Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA

⁶Hillman Cancer Center, University of Pittsburgh Medical Center and Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA

⁷Ministry of Health, Hanoi, Vietnam

Keywords

Introduction

Breast cancer is the most common cancer and the leading cause of death for women worldwide. The GLOBOCAN reported that there were 2.2 million new cases of breast cancer worldwide in 2020, accounting for a quarter of cancer cases among women.¹ In Vietnam, the incidence rate for breast cancer was 34.2 per 100 000 women, making it the most common cancer for women (25.8% of all cancers) and the fourth leading cause of cancer death overall, following lung cancer, liver cancer, and stomach cancer.¹

In the past few decades, breast cancer incidence rates have increased in developing countries, including Vietnam. Rising rates coincide with changes in lifestyle, population characteristics, and menstrual and reproductive patterns in these countries.¹ These changes include factors such as an increase of physical inactivity, obesity, dietary fat intake, alcohol consumption, early onset of menarche, late onset of menopause, nulliparity, late age at first birth, a decreased number of childbirths, and no or shortened duration of breastfeeding.^{2,3}

Prior studies have consistently shown that prolonged endogenous and exogenous estrogen exposure increases the risk of breast cancer.⁴ A meta-analysis of 117 studies in 2012 reported the associations between age at primiparity, parity, and at menopause with the risk of breast cancer.² Fewer parities and advanced age at first birth both increased the risk of ER+/PR+ cancer, but they were not associated with the risk of ER-/PR-cancer in most prospective studies.⁶ A meta-analysis evaluated 15 studies, with 21 941 breast cancer patients and 864 177 controls, that investigated the impact of reproductive behaviors according to intrinsic subtype.⁷ Parity and breastfeeding were associated with a reduced risk of developing luminal subtype, while later age at first birth was related to an increased risk of developing luminal subtype.⁷ Breastfeeding was associated with a reduced risk of developing triple-negative breast cancer (TNBC) subtype. [/] Research on other reproductive factors, such as spontaneous abortion (SA) or induced abortion (IA), with breast cancer risk has yielded inconsistent findings. A 2015 meta-analysis of 15 prospective studies revealed non-significant associations of breast cancer with SA and IA.⁸ These subtypes (luminal A, luminal B, HER2+, and TNBC) differ in age at diagnosis and prognosis. In addition, they may also differ etiologically and have different in risk factors.9

Vietnamese women are experiencing significant changes in lifestyle and reproductive patterns. However, little is known about how these changes affect breast cancer risk. To our knowledge, only two small-scale studies on breast cancer have been conducted in Vietnam and the results were inconsistent.^{10,11} Herein, we report results from a large casecontrol study, the Vietnamese Breast Cancer Study (VBCS), focusing on the associations between menstrual and reproductive factors with breast cancer risk among Vietnamese women.

Methods

Study Population

We recruited newly diagnosed breast cancer patients (clinical diagnosis) aged 21 to 79 from inpatient surgical and chemotherapy units and outpatient units of the Vietnam National Cancer Hospital and the Hanoi Oncology Hospital. These are the two largest oncology hospitals in Northern Vietnam. Breast cancer patients with a prior history of cancer were not eligible for the study. Controls were selected from healthy relatives, neighbors, or friends of breast cancer patients (n = 64), or healthy women who were taking care of other cancer patients at these two hospitals (n = 402), and frequency was matched to cases on age (±3 years) and residence (urban/rural). Controls were recruited at approximately the same time as case recruiment. Women who had a history of cancer diagnosis were excluded from this study. Details of design and methods for the VBCS have been described previously.¹²

A total of 501 newly diagnosed breast cancer patients and 468 controls were included in this study from July 2017 to June 2018 in Hanoi, Vietnam (response rates of 93.1% and 97.7% for cases and controls, respectively). We excluded case participants who were subsequently confirmed to have a benign tumor based on a pathological review (n = 9) or who were diagnosed at stage 0 (n = 2). Finally, 490 cases and 468 controls remained in the current study. Our study initially applied an age frequency matched design. However, during data collection, it was adapted to the individual matching study, in which cases and controls were individually matched to cases on age (± 3 years), city, and province of residency. Thus, out of 490 cases and 468 controls, there are 374 individually matched case-control pairs. All patient information was de-identified. The protocol of this study was approved by the Vietnam National Cancer Institute (No.160530 - IRB approval issued May 30, 2016) and Vanderbilt University Medical Center (No.161039 "Vietnam Center of Research Excellence (V-CORE) - IRB approval issued May 31, 2018"). All patients provided written informed consent prior to enrollment in the study.

Assessment of Menstrual and Reproductive Characteristics

Information on menstrual and reproductive characteristics, demographics, lifestyle factors, medical history, and familial cancer history was collected through in-person interviews using a structured questionnaire built within the Research Electronic Data Capture (REDCap) mobile application.¹³ In addition, anthropometrics, weight, height, waist, and hip circumferences were taken by trained interviewers following a standard protocol, from which body mass index (BMI) was calculated as weight (kg)/[height (m)].² Data collected for the current study included age, marital status, residency (urban, rural), age at first menarche, age at menopause, menstrual cycle regularity and duration, parity, age at first live birth, age at last live birth, number of pregnancies and abortions, and total months of breastfeeding in a lifetime. Additionally, p postmenopausal status was defined as cease of menstruation naturally (i.e., excluding those brought on by pregnancy, surgery, or other treatments) for at least 12 months.

Menstrual and reproductive factors and covariates were categorized as follows in the study: age at menarche (<13 vs. ≥13 years, similar to publications from other Asian countries^{14,15}), menopausal status (premenopausal vs. postmenopausal), age at menopause (<50 vs. \geq 50 years), regularity of menstrual cycle (i.e., regular, irregular, sometimes irregular), length of the menstrual cycle (<26 days, 26-30 days, >30 days), number of pregnancies $(0, 1, 2, 3, \geq 4)$, parity (ever vs. never), number of livebirth $(1, 2, \geq 3)$, age at first live birth (<25, 25-29, 30-34, \geq 35 years), abortion (never, induced only, miscarriage only, both induced and miscarriage), breastfeeding (ever vs. never), breastfeeding duration (<12, 12-23, ≥24 months), and family history of breast cancer (no vs. yes). Body mass index (BMI) was categorized using the World Health Organization's classification for Asian populations: underweight (BMI < 18.5 kg/m^2), normal/healthy weight (BMI ranges from 18.5 to 22.9 kg/m²), overweight (BMI ranges from 23 to 27.5 kg/m²) and obese (BMI > 27.5 kg/m²). Economic status was defined by annual family income (i.e., ≤50 million, 50-100 million, 100-150 million, 150-200 million, >200 million).¹⁶

Data on ER/PR status and HER-2 expression was collected by reviewing medical charts from the Vietnam National Cancer Hospital and the Hanoi Oncology Hospital. ER and PR status, HER-2 expression, and Ki67 status were assessed by immunohistochemistry (IHC). Intrinsic tumor subtypes were classified as luminal A (ER-positive and/or PR-positive, HER-2 negative, and low Ki-67), luminal B (ER-positive and/or PR-positive, and HER-2 positive or HER-2 negative with high Ki-67), HER-2 overexpressing (ER-negative and PR negative, and HER-2 positive; HER 2+), and triple-negative (ER, PR, and HER-2 negative; TNBC).

Statistical Analysis

Differences in frequency distribution of categorical variables were evaluated by Pearson chi-square, while the Student t-test was performed to compare mean values of continuous variables between cases and controls. Unconditional logistic regression models were used to estimate odds ratios (ORs) and their respective 95% confidence intervals (CIs) for associations of breast cancer risk with menstrual and reproductive characteristics. The differences in ORs between the two groups, pre- and post-menopausal, was tested using Likelihood ratio tests. The multivariable logistic regression model was adjusted for potential confounders based on the literature. Tests for trends across categories were performed by assigning the median value for each category. Multivariable multinomial logistic regression was also performed to evaluate whether the observed risk estimates varied across molecular subtypes of breast cancer. We used likelihood ratio tests to evaluate heterogeneity across molecular subtypes. All analyses were performed using R version 4.1.0. A two-sided P-value of less than .05 was considered statistically significant.

The reporting of this study conforms to STROBE guidelines.¹⁷

Results

The distribution of participant characteristics is presented in Table 1. The age at diagnosis for cases ranged from 21 to 78 years, with a mean of 50.1 (standard deviation-SD = 9.8) years. The mean age for the control group was 49.9 (SD = 9.3) years. There were no significant differences between cases and controls in levels of education, marital status, residence, BMI, or family history of cancer among first-degree relatives. However, compared with controls, fewer cases had an annual family income >200 million Vietnamese Dong (VND). Our previous study described the characteristics of cases, in which 94 (19.2%) participants were diagnosed at stage I, 240 (49.2%) were diagnosed at stage III and IV.¹⁸

Table 2 shows the ORs and 95% CIs for breast cancer associated with menstrual and reproductive factors. The vast majority of study participants (95.2% of cases and 97.1% of controls) started menstruation at age 13 or later. Early age at menarche (<13 years) was associated with a non-significantly evaluated breast cancer risk (OR = 1.69, 95% CI: .85-3.49) compared to menarche age of 13 or older. A significantly increased risk of breast cancer was found among women with a later age at menopause (OR = 1.71, 95% CI: 1.15-2.57), compared to women with an earlier age at menopause. Compared with participants who had regular ovulatory menstrual cycles, women with irregular ovulatory menstrual cycles had a 48% (95% CI: .37-.71) lower risk of breast cancer, while participants with sometimes irregular menstrual cycles had a 3.49-fold (95% CI: 1.74-7.66) increased risk of breast cancer. Compared with controls, breast cancer cases

were more likely to have fewer pregnancies and live births and were older at first live birth. Compared to women with one child, women with three or more children had a 47% (95% CI: .33-.85) reduced risk of breast cancer. In contrast, age at last birth was not associated with breast cancer risk (data not shown). History and number of spontaneous miscarriages, induced abortions, status, and duration of breastfeeding were not associated with breast cancer risk. Sensitivity analyses based on 374 individually matched pairs did not materially change the above-reported associations (Supplementary Tables S1).

Further analyses stratified by menopausal status were conducted and the results are shown in Table 3. The association of breast cancer with age at menarche, parity, and age at first live birth were predominantly seen among premenopausal women. The associations for early age at menarche (OR = 2.66, 95% CI: 1.08-7.51, P_{heterogeneity} = .05) and number of live births with breast cancer (OR = .42, 95% CI: .21-.83) reached the statistical significance level. In addition, compared to women with a BMI of <18.5 kg/m², women with a BMI of 23-17.5 kg/m² experienced an increased risk of breast cancer among those who were postmenopausal (OR = 2.18, 95% CI: 1.08-4.49, P_{heterogeneity} = .04).

Table 4 presents the associations between menstrual and reproductive characteristics and the risk of intrinsic breast cancer subtypes. Among breast cancer patients, luminal B subtype was most frequent (48.6%), followed by HER2enriched (24.5%), luminal A (16.7%), and triple-negative breast cancer (TNBC; 10.2%). Menarche at an early age (<13 years) was associated with a significantly increased risk of luminal A (OR = 3.06, 95% CI: 1.04-8.16) and nonsignificantly increased HER2-enriched (OR = 1.93, 95%) CI: .66-5.06) and TNBC (OR = 2.45, 95% CI: .54-8.25). Compared to women with one child, women with more than two children experienced a reduced risk of luminal B breast cancer (OR = .43, 95% CI: .24-.79) and TNBC (OR = .34, 95% CI: .14-.89), respectively. The risk of HER2-enriched breast cancer increased significantly (OR = 2.19, 95% CI: 1.14-4.23) with more advanced age at menopause. We observed no other significant associations for specific subtypes of breast cancer.

Discussion

To our knowledge, this study is the largest case-control study of breast cancer and the first one to investigate breast cancer risk factors by tumor subtype in Vietnam. Most of our findings on menstrual/reproductive characteristic-breast cancer risk associations are consistent with those reported for Western and other Asian populations, while few previously established associations were not observed in our study.

Early age at menarche has been consistently associated with an increased risk of breast cancer in several Asian and Western populations.¹⁹⁻²⁴ In our study, early age at menarche was associated with a non-significantly elevated risk of breast

 Table 1. Sociodemographic characteristics and familial cancer

 history of study participants.

	Cases	Controls	P value
Variables	(N = 490)	(N = 468)	
Age [mean ± SD (y)]	50.1 ± 9.8	49.9 ± 9.3	.74
Education level (n (%))			
No formal education	7 (1.4)	7 (1.5)	.87
Elementary school	65 (13.3)	60 (12.8)	
Middle school and high school	324 (66.3)	321 (68.5)	
College and higher	93 (19.0)	80 (17.2)	
Marital status (n (%))			
Single	76 (15.5)	52 (11.1)	.06
Married or cohabiting	413 (84.5)	416 (88.9)	
Annual family income (VND) (n (%))		
≤50 million	144 (29.7)	145 (31.5)	.009
50-100 million	189 (39.0)	163 (35.4)	
100-150 million	103 (21.1)	93 (20.2)	
150-200 million	40 (8.2)	31 (6.7)	
>200 million	9 (1.8)	29 (6.3)	
Residence (n (%))			
Urban	122 (24.9)	107 (23.1)	.75
Suburban	71 (14.5)	65 (14.0)	
Rural	296 (60.5)	291 (62.9)	
BMI (n (%))			
mean ± SD (y)]	21.7 ± 2.5	21.5 ± 2.7	.37
<18.5 kg/m ²	45 (9.2)	55 (11.8)	.42
18.5-22.9 kg/m ²	303 (62.1)	288 (61.7)	
23-27.5 kg/m ²	131 (26.8)	112 (24.0)	
>27.5 kg/m ²	9 (1.9)	12 (3.5)	
Familial cancer history (n (%))			
No	384 (78.4)	359 (76.9)	.63
Yes	106 (21.6)	108 (23.1)	

cancer overall. This association became significant among premenopausal women and for luminal A breast cancer. These findings are consistent with previous studies that showed the association between menarche and breast cancer was stronger for the luminal A subtype.^{15,25,26} Early-onset of menarche was related to early and greater cumulative exposure to estrogen, in which the presence of progesterone can increase the risk of breast cancer, particularly in the luminal A subtype in which estrogen exposure is most relevant. We found that the menarche-breast cancer association was mainly confined to premenopausal women is likely caused by a cohort effect as Vietnamese women traditionally have a late onset of menstruation (more than 97% of control participants began menstruation at \geq 13 years of age). In addition, the age at menarche has decreased in younger generations. In our study, the average menarche age among controls was 15.7 years.

We found that women with irregular cycles had 48% and 56% reduced risks of breast cancer overall and for luminal B breast cancer, respectively. This finding is in line with reports from previous studies.^{27,28} Irregular menstrual cycles may be

Variables N (%) N (%) OR (95% CI) ¹ Age at menarche <13 454 (95.2) 443 (97.1) 1.00 (ref) <13 23 (48) 13 (2.9) 1.69 (85.3.49) Menopause		Cases	Controls	OR (95% CI) ^a	
Age at menarche 213 454 (95.2) 443 (97.1) 1.00 (ref) <13 23 (48) 13 (2.9) 1.69 (85-3.49) Menopause No 260 (53.5) 246 (53.0) 1.00 (ref) Yes 260 (46.5) 218 (47.0) 90 (62-1.31) Age at menopause So 112 (49.6) 137 (62.8) 1.00 (ref) 250 114 (50.4) 81 (37.2) 1.71 (1.15-2.57) Regular menstrual cycle 324 (69.4) 1.00 (ref) Irregular 80 (16.5) 133 (28.5) .52 (37.7) 53 (37.4) 10 (2.1) .34 (17.47-66 Carght of menstrual cycle 23 (49.7) 24 (69.4) 1.00 (ref) 24 (47.9) 24 (42.96) 24 (42.96) 34 (42.96) <th>Variables</th> <th>N (%)</th> <th>N (%)</th>	Variables	N (%)	N (%)		
-13 454 (95.2) 443 (97.1) 1.00 (ref) <13 23 (4.8) 13 (2.9) 1.69 (85-3.49) Menopause	Age at menarche				
<13	≥13	454 (95.2)	443 (97.1)	1.00 (ref)	
Menopause Intervention Intervention No 260 (53 5) 246 (53 0) 1.00 (ref) Age at menopause	< 3	23 (4.8)	13 (2.9)	1.69 (.85-3.49)	
No 260 (53.5) 246 (53.0) 1.00 (ref) Yes 226 (46.5) 218 (47.0) .90 (62-1.31) Age at menopause	Menopause				
Yes 226 (46.5) 218 (47.0) .90 (62 -1.31) Age at menopause	No	260 (53.5)	246 (53.0)	1.00 (ref)	
Age at menopause C <thc< th=""> C <thc< th=""></thc<></thc<>	Yes	226 (46.5)	218 (47.0)	.90 (.62-1.31)	
350 112 (49.6) 137 (62.8) 1.00 (ref) 250 114 (50.4) 81 (37.2) 1.71 (1.15-2.57) Regular menstrual cycle regular 370 (76.1) 324 (69.4) 1.00 (ref) Irregular 80 (16.5) 133 (28.5) 52 (37.7) Sometimes 52 (37.7) Sometimes 36 (7.4) 10 (2.1) 3.49 (1.74-7.66) Common c	Age at menopause	· · · · ·		()	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	<50	2 (49.6)	137 (62.8)	1.00 (ref)	
Regular In (101) In (101) In (101) Regular 370 (76.1) 324 (69.4) 1.00 (ref) Irregular 80 (16.5) 133 (28.5) 5.2 (37.7) Sometimes 36 (7.4) 10 (2.1) 3.49 (1.74.7.66 Length of menstrual cycle	>50	114 (50.4)	81 (37.2)	1.71 (1.15-2.57)	
Regular 370 (76.1) 324 (69.4) 1.00 (ref) Irregular 80 (16.5) 133 (28.5) .52 (37.7) Sometimes 36 (7.4) 10 (2.1) 349 (1.74-7.66) Length of menstrual cycle ************************************	Regular menstrual cycle				
Inequar BO (16.5) 12 (2.5) 1.5 (37.71) Sometimes 36 (7.4) 10 (2.1) 3.49 (17.47.66 Length of menstrual cycle	Regular	370 (76 1)	324 (69.4)	1.00 (ref)	
Inspan 56 (0.7) 10 (2.1) 3.4 (1.74) Sometimes 36 (7.4) 10 (2.1) 3.4 (1.74) Length of menstrual cycle	Irregular	80 (16.5)	133 (28.5)	52 (37-71)	
Contention Description Description Description Description Description 2630 days 221 (602) 205 (63.3) .46 (28.76) 2630 days 61 (16.6) 71 (21.9) .64 (42.96) Trend test P = .004 Number of pregnancies P = .004 0 28 (5.7) 27 (5.8) 1.00 (ref) 1 34 (7.0) 19 (4.1) 1.46 (67.32.1) 2 66 (13.6) 71 (15.2) .82 (42-1.57) 3 1.17 (24.0) 110 (23.6) .92 (49-1.71) 24 242 (49.7) 240 (51.4) .85 (47-1.53) Parity P = .30	Sometimes	36 (74)	10(21)	3 49 (1 74-7 66)	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Length of menstrual cycle	30 (7.1)	10 (2.1)	5.17 (1.71-7.00)	
26-30 days 21 (60.2) 20 (14.0) 1.00 (16.0) >30 days 61 (16.6) 71 (21.9) .64 (.42.96) Trend test P = .004 Number of pregnancies 0 0 28 (5.7) 27 (5.8) 1.00 (ref) 1 34 (7.0) 19 (4.1) 1.46 (.67.3.21) 2 66 (13.6) 71 (15.2) .82 (.42.1.57) 3 117 (24.0) 110 (23.6) .92 (.49.1.71) >4 .24 (49.7) .240 (51.4) .85 (.47.1.53) Parity P = .30 Parity P = .30 Ever 451 (92.6) 433 (92.9) 1.00 (ref) Number of live births 1 1.9 (.71.2.01) 1.00 (ref) 1 61 (13.3) 39 (9.0) 1.00 (ref) 2 .254 (56.3) .229 (.52.9) .74 (.47.1.15) >3 137 (30.4) 165 (38.1) .53 (.33.85) Trend test P = .005	<26 days	85 (23.2)	49 (14 9)	1.00 (rof)	
22-0 days 221 (60.2) 205 (53.3) +6 (22.76) 7rend test P = .004 Number of pregnancies P = .004 0 28 (5.7) 27 (5.8) 1.00 (ref) 1 34 (7.0) 19 (4.1) 1.46 (6.7-3.21) 2 66 (13.6) 71 (15.2) .82 (42-1.57) 3 117 (24.0) 110 (23.6) .92 (49-1.71) ≥4 242 (49.7) 240 (51.4) .85 (47-1.53) Trend test P = .30 Parity Perator Ever 451 (92.6) 433 (92.9) 1.00 (ref) Number of live births I 1.03 (7.4) 33 (7.1) 1.19 (71-2.01) Number of live births I	~20 days	221 ((0.2)	205 (C2 2)	1.00 (Tel)	
JO days b1 (1.6) J1 (21.9) b1 (42.76) Trend test P = .004 Number of pregnancies P = .004 0 28 (5.7) 27 (5.8) 1.00 (ref) 1 34 (7.0) 19 (4.1) 1.46 (42.76) 2 66 (13.6) 71 (15.2) 82 (42-1.57) 3 117 (24.0) 110 (23.6) 92 (49-1.7) ≥4 242 (49.7) 240 (51.4) 85 (47.1.53) Trend test P = .30 Parity P = .30 Parity V	26-30 days	221 (60.2)	205 (63.3)	.46 (.2876)	
Trend test P = .0.04 Number of pregnancies 28 (5.7) 27 (5.8) 1.00 (ref) 1 34 (7.0) 19 (4.1) 1.46 (6.73.21) 2 66 (13.6) 71 (15.2) .82 (42-1.57) 3 117 (24.0) 110 (22.6) .92 (42-1.7) ≥4 242 (49.7) 240 (51.4) .85 (47-1.53) Trend test P = .30 Parity Pe = .30 Ever 451 (92.6) 433 (92.9) 1.00 (ref) Never 36 (7.4) 33 (7.1) 1.19 (71-2.01) Number of live births 1 61 (13.3) 39 (9.0) 1.00 (ref) 2 254 (56.3) 229 (52.9) .74 (47-1.15) ≥3 137 (30.4) 165 (38.1) .53 (33.85) Trend test P = .005 P = .005 Age at first live birth ^b	>30 days	61 (16.6)	71 (21.9)	.64 (.4296)	
Number of pregnancies 0 28 (5.7) 27 (5.8) 1.00 (ref) 1 34 (7.0) 19 (4.1) 1.46 (67-3.21) 2 66 (13.6) 71 (15.2) .82 (42-1.57) 3 117 (24.0) 110 (23.6) .92 (49-1.1) ≥4 242 (49.7) 240 (51.4) .85 (47-1.53) Trend test P = .30 Parity	I rend test			P = .004	
0 28 (5.7) 27 (5.8) 1.00 (ref) 1 34 (7.0) 19 (4.1) 1.46 (67-3.21) 2 66 (13.6) 71 (15.2) .82 (42-1.57) 3 117 (24.0) 110 (23.6) .92 (49-1.71) ≥4 242 (49.7) 240 (51.4) .85 (47-1.53) Parity P = .30 Party P = .30 Ever 451 (92.6) 433 (92.9) 1.00 (ref) Number of live births I 1.19 (.71-2.01) Number of live births I .92 (52.9) .74 (47-1.15) 2 254 (56.3) 229 (52.9) .74 (47-1.15) 3.3 137 (30.4) 165 (38.1) .53 (33.285) Trend test P = .005 Age at first live birth ^b V <2.5	Number of pregnancies		27 (5.0)		
1 34 (7.0) 19 (4.1) 1.46 (67-3.21) 2 66 (13.6) 71 (15.2) .82 (42-1.57) 3 117 (24.0) 110 (23.6) .92 (49-1.71) ≥4 242 (49.7) 240 (51.4) .85 (47-1.53) Parity P = .30 Parity	0	28 (5.7)	27 (5.8)	1.00 (ref)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		34 (7.0)	19 (4.1)	1.46 (.67-3.21)	
3 117 (24.0) 110 (23.6) .92 (49.1.7) ≥4 242 (49.7) 240 (51.4) .85 (47.1.53) Trend test P = .30 Parity Ever .451 (92.6) .433 (92.9) 1.00 (ref) Never 36 (7.4) .33 (7.1) 1.19 (.71.2.01) Number of live births I .61 (13.3) .39 (9.0) 1.00 (ref) 2 .254 (56.3) .229 (52.9) .74 (.47.1.15) ≥3 .137 (30.4) .165 (38.1) .53 (.33.85) Trend test P = .005 Age at first live birth ^b	2	66 (13.6)	71 (15.2)	.82 (.42-1.57)	
	3	117 (24.0)	110 (23.6)	.92 (.49-1.71)	
Trend test P = .30 Parity Parity Ever 451 (92.6) 433 (92.9) 1.00 (ref) Never 36 (7.4) 33 (7.1) 1.19 (7.1-2.01) Number of live births I 61 (13.3) 39 (9.0) 1.00 (ref) 2 254 (56.3) 229 (52.9) .74 (47-1.15) ≥3 137 (30.4) 165 (38.1) .53 (3.3-85) Trend test P = .005 Age at first live birth ^b P = .005 <25 246 (54.5) 279 (64.7) 1.00 (ref) 25-29 153 (33.9) 118 (27.4) 1.49 (1.10-2.02) 30-34 28 (6.2) 21 (4.9) 1.40 (75-2.63) ≥35 24 (5.4) 13 (3.0) 1.66 (76-3.71) Trend test P = .029 Abortion P = .029 Abortion P = .029 Both induced only 71 (14.6) 72 (15.4) 1.00 (ref) Induced only 91 (40.4) 170 (36.4) 1.19 (87-1.61) Both induced and miscarriage 58 (11.9) 56 (12.0) 1.00 (ref) Never <t< td=""><td>≥4</td><td>242 (49.7)</td><td>240 (51.4)</td><td>.85 (.47-1.53)</td></t<>	≥4	242 (49.7)	240 (51.4)	.85 (.47-1.53)	
Parity Ever $451 (92.6)$ $433 (92.9)$ $1.00 (ref)$ Never $36 (7.4)$ $33 (7.1)$ $1.19 (7.1-2.01)$ Number of live births 1 $61 (13.3)$ $39 (9.0)$ $1.00 (ref)$ 2 $254 (56.3)$ $229 (52.9)$ $.74 (47-1.15)$ ≥ 3 $137 (30.4)$ $165 (38.1)$ $.53 (33.8.5)$ Trend test $P = 0.05$ Age at first live birth ^b $<25 (52.9)$ $.140 (.75-2.63)$ Age at first live birth ^b $<25 (2.2)$ $.149 (1.10-2.02)$ $.30.34$ $.28 (6.2)$ $.21 (4.9)$ $.140 (.75-2.63)$ $_{235}$ $246 (54.5)$ $.279 (64.7)$ $.1.66 (.76-3.71)$ $P = .029$ 30.34 $28 (6.2)$ $.21 (4.9)$ $.140 (.75-2.63)$ $.23 (3.0)$ $.166 (.76-3.71)$ Trend test P $.029$ P $.929$ P $.929$ Abortion P $.029$ $.929$ $.929 (14.9)$ $.100 (ref)$ $.19 (87-1.61)$ $.19 (87-1.61)$ Both induced and miscarriage $.58 (11.9)$ $.56 (12.0)$ $.102 (.66-1.58)$ $.929 (.56-1.58)$ $.929 (.56-1.58)$	Trend test			P = .30	
Ever $451 (92.6)$ $433 (92.9)$ $1.00 (ref)$ Never $36 (7.4)$ $33 (7.1)$ $1.19 (.71-2.01)$ Number of live births i $61 (13.3)$ $39 (9.0)$ $1.00 (ref)$ 2 $254 (56.3)$ $229 (52.9)$ $.74 (47-1.15)$ ≥ 3 $137 (30.4)$ $165 (38.1)$ $.53 (33.85)$ Trend test $P = .005$ Age at first live birth ^b v v <25 $246 (54.5)$ $279 (64.7)$ $1.00 (ref)$ $25-29$ $153 (33.9)$ $118 (27.4)$ $1.49 (1.10-2.02)$ 30.34 $28 (6.2)$ $21 (4.9)$ $1.40 (.75-2.63)$ ≥ 35 $24 (5.4)$ $13 (3.0)$ $1.66 (.76-3.71)$ Trend test $P = .029$ Abortion $P = .029$ Abortion $Never$ $161 (33.1)$ $169 (36.2)$ $1.00 (ref)$ Induced only $71 (14.6)$ $72 (15.4)$ $1.00 (ref)$ Induced only $197 (40.4)$ $170 (36.4)$ $1.19 (.87-1.61)$ Both induced and miscarriage $58 (11.9)$ $56 (12.0)$ $1.02 (.66-1.58)$ Breastfeeding ^b v $443 (91.0)$ $426 (91.4)$ $1.00 (ref)$ Never $443 (91.0)$ $426 (91.4)$ $1.00 (ref)$ Never $44 (9.0)$ $40 (8.6)$ $1.49 (.55-4.39)$ Breastfeeding duration ^b v $15 (3.4)$ $13 (3.1)$ $1.00 (ref)$ $12-23$ $115 (26.1)$ $103 (24.1)$ $1.01 (.45-2.8)$	Parity				
Never $36 (7.4)$ $33 (7.1)$ $1.19 (.71-2.01)$ Number of live birthsII $61 (13.3)$ $39 (9.0)$ $1.00 (ref)$ 2 $254 (56.3)$ $229 (52.9)$ $.74 (.47-1.15)$ ≥ 3 $137 (30.4)$ $165 (38.1)$ $.53 (33.85)$ Trend testP = .005Age at first live birth ^b $= 25$ $246 (54.5)$ $279 (64.7)$ $1.00 (ref)$ $25-29$ $153 (33.9)$ $118 (27.4)$ $1.49 (1.10-2.02)$ $30-34$ $28 (6.2)$ $21 (4.9)$ $1.40 (.75-2.63)$ ≥ 35 $24 (54.4)$ $13 (3.0)$ $1.66 (.76-3.71)$ Trend testP = .029AbortionP = .029AbortionP = .029Never $161 (33.1)$ $169 (36.2)$ $1.00 (ref)$ Induced only $71 (14.6)$ $72 (15.4)$ $1.06 (.71-1.58)$ Miscarriage only $197 (40.4)$ $170 (36.4)$ $1.19 (.87-1.61)$ Both induced and miscarriage $58 (11.9)$ $56 (12.0)$ $1.02 (.66-1.58)$ Breastfeeding ^b $=$ $=$ $-$ Ever $443 (91.0)$ $426 (91.4)$ $1.00 (ref)$ Never $44 (9.0)$ $40 (8.6)$ $1.49 (.55-4.39)$ Breastfeeding duration ^b $=$ $ <12 1 15 (25.1)$ $103 (24.1)$ $1.01 (.45-2.28)$	Ever	451 (92.6)	433 (92.9)	I.00 (ref)	
Number of live births I 61 (13.3) 39 (9.0) 1.00 (ref) 2 254 (56.3) 229 (52.9) .74 (47-1.15) ≥3 137 (30.4) 165 (38.1) .53 (3385) Trend test P = .005 Age at first live birth ^b	Never	36 (7.4)	33 (7.1)	1.19 (.71-2.01)	
I61 (13.3)39 (9.0)1.00 (ref)2254 (56.3)229 (52.9).74 (47-1.15) ≥ 3 137 (30.4)165 (38.1).53 (33.85)Trend testP = .005Age at first live birth ^b	Number of live births				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	I	61 (13.3)	39 (9.0)	1.00 (ref)	
	2	254 (56.3)	229 (52.9)	.74 (.47-1.15)	
Trend testP = .005Age at first live birth ^b <25 246 (54.5)279 (64.7)1.00 (ref)25-29153 (33.9)118 (27.4)1.49 (1.10-2.02)30-3428 (6.2)21 (4.9)1.40 (.75-2.63) \geq 3524 (5.4)13 (3.0)1.66 (.76-3.71)Trend testP = .029AbortionP = .029AbortionP = .029Never161 (33.1)169 (36.2)1.00 (ref)Induced only71 (14.6)72 (15.4)1.06 (.71-1.58)Miscarriage only197 (40.4)170 (36.4)1.19 (.87-1.61)Both induced and miscarriage58 (11.9)56 (12.0)1.02 (.66-1.58)Breastfeeding ^b Ever443 (91.0)426 (91.4)1.00 (ref)Never15 (3.4)13 (3.1)1.00 (ref)Lever15 (3.4)13 (3.1)1.00 (ref)Lever15 (3.4)13 (3.1)1.00 (ref)Lever15 (26.1)103 (24.1)1.01 (.45-2.28)	≥3	137 (30.4)	165 (38.1)	.53 (.3385)	
Age at first live birth ^b 246 (54.5) 279 (64.7) 1.00 (ref) $25-29$ 153 (33.9) 118 (27.4) 1.49 (1.10-2.02) $30-34$ 28 (6.2) 21 (4.9) 1.40 (.75-2.63) ≥ 35 24 (5.4) 13 (3.0) 1.66 (.76-3.71) Trend test P = .029 Abortion P = .029 Never 161 (33.1) 169 (36.2) 1.00 (ref) Induced only 71 (14.6) 72 (15.4) 1.06 (.71-1.58) Miscarriage only 197 (40.4) 170 (36.4) 1.19 (.87-1.61) Both induced and miscarriage 58 (11.9) 56 (12.0) 1.02 (.66-1.58) Breastfeeding ^b Image: Second Seco	Trend test			P = .005	
<25 246 (54.5) 279 (64.7) 1.00 (ref) $25-29$ 153 (33.9) 118 (27.4) 1.49 (1.10-2.02) $30-34$ 28 (6.2) 21 (4.9) 1.40 (.75-2.63) ≥ 35 24 (5.4) 13 (3.0) 1.66 (.76-3.71)Trend testP = .029AbortionPNever 161 (33.1) 169 (36.2) 1.00 (ref)Induced only 71 (14.6) 72 (15.4) 1.06 (.71-1.58)Miscarriage only 197 (40.4) 170 (36.4) 1.19 (.87-1.61)Both induced and miscarriage 58 (11.9) 56 (12.0) 1.02 (.66-1.58)Breastfeeding ^b V V V V Ever 443 (91.0) 426 (91.4) 1.00 (ref)Never 44 (9.0) 40 (8.6) 1.49 (.55-4.39)Breastfeeding duration ^b V V V <12 15 (3.4) 13 (3.1) 1.00 (ref) $12-23$ 115 (26.1) 103 (24.1) 1.01 (.45-2.28)	Age at first live hirth ^b			1 .000	
25-29153 (33.9)118 (27.4)1.49 (1.10-2.02)30-3428 (6.2)21 (4.9)1.40 (.75-2.63) \geq 3524 (5.4)13 (3.0)1.66 (.76-3.71)Trend testP = .029Abortion71 (14.6)72 (15.4)1.00 (ref)Induced only71 (14.6)72 (15.4)1.00 (ref)Induced and miscarriage58 (11.9)56 (12.0)1.02 (.66-1.58)BreastfeedingbEver443 (91.0)426 (91.4)1.00 (ref)Never44 (9.0)40 (8.6)1.49 (.55-4.39)Breastfeeding durationb15 (3.4)13 (3.1)1.00 (ref)12-23115 (26.1)103 (24.1)1.01 (.45-2.28)	<25	246 (54 5)	279 (647)	LOO (ref)	
$30-34$ $28 (6.2)$ $21 (4.9)$ $1.40 (.75-2.63)$ ≥ 35 $24 (5.4)$ $13 (3.0)$ $1.66 (.76-3.71)$ Trend test $P = .029$ Abortion $P = .029$ Never $161 (33.1)$ $169 (36.2)$ $1.00 (ref)$ Induced only $71 (14.6)$ $72 (15.4)$ $1.06 (.71-1.58)$ Miscarriage only $197 (40.4)$ $170 (36.4)$ $1.19 (.87-1.61)$ Both induced and miscarriage $58 (11.9)$ $56 (12.0)$ $1.00 (ref)$ Never $443 (91.0)$ $426 (91.4)$ $1.00 (ref)$ Never $44 (9.0)$ $40 (8.6)$ $1.49 (.55-4.39)$ Breastfeeding duration ^b $(15 (3.4)$ $13 (3.1)$ $1.00 (ref)$ $(22 3)$ $115 (26.1)$ $103 (24.1)$ $1.01 (.45-2.28)$	25	153 (33.9)	118(274)	1.00 (10)	
30534 $20(0.2)$ $21(4.7)$ $1.40(.732.03)$ ≥ 35 $24(5.4)$ $13(3.0)$ $1.66(.76-3.71)$ Trend testP = .029Abortion $P = .029$ Never161(33.1)169(36.2) 1.00 (ref)Induced only71(14.6)72(15.4) $1.06(.71-1.58)$ Miscarriage only197(40.4)170(36.4) $1.19(.87-1.61)$ Both induced and miscarriage58(11.9)56(12.0) $1.02(.66-1.58)$ Breastfeeding ^b V V V Ever443(91.0)426(91.4) 1.00 (ref)Never444(9.0)40(8.6) $1.49(.55-4.39)$ Breastfeeding duration ^b V V V < 12 $15(3.4)$ $13(3.1)$ 1.00 (ref) $12-23$ $115(26.1)$ $103(24.1)$ $1.01(.45-2.28)$	20-27	28 (6 2)	21 (4 9)	1.40(75.263)	
25315 (3.4)15 (3.0)1.00 (.76-3.71)Trend testP = .029AbortionNever161 (33.1)169 (36.2)1.00 (ref)Induced only71 (14.6)72 (15.4)1.06 (.71-1.58)Miscarriage only197 (40.4)170 (36.4)1.19 (.87-1.61)Both induced and miscarriage58 (11.9)56 (12.0)1.02 (.66-1.58)Breastfeeding ^b Ever443 (91.0)426 (91.4)1.00 (ref)Never444 (9.0)40 (8.6)1.49 (.55-4.39)Breastfeeding duration ^b 15 (3.4)13 (3.1)1.00 (ref)12.23115 (26.1)103 (24.1)1.01 (.45-2.28)	>)-)- >)-)-	20 (6.2)	21 (3.0)	1.40(.75-2.03)	
Abortion I 61 (33.1) I 69 (36.2) I.00 (ref) Induced only 71 (14.6) 72 (15.4) I.06 (.71-1.58) Miscarriage only I 97 (40.4) I 70 (36.4) I.19 (.87-1.61) Both induced and miscarriage 58 (11.9) 56 (12.0) I.02 (.66-1.58) Breastfeeding ^b Ever 443 (91.0) 426 (91.4) I.00 (ref) Never 444 (9.0) 40 (8.6) I.49 (.55-4.39) Breastfeeding duration ^b 15 (3.4) I 3 (3.1) I.00 (ref) <12	≥33 Trand test	24 (3.4)	13 (3.0)	1.00(.70-3.71)	
Abortion I 61 (33.1) I 69 (36.2) I.00 (ref) Induced only 71 (14.6) 72 (15.4) 1.06 (.71-1.58) Miscarriage only 197 (40.4) 170 (36.4) 1.19 (.87-1.61) Both induced and miscarriage 58 (11.9) 56 (12.0) 1.02 (.66-1.58) Breastfeeding ^b Ever 443 (91.0) 426 (91.4) 1.00 (ref) Never 444 (9.0) 40 (8.6) 1.49 (.55-4.39) Breastfeeding duration ^b 15 (3.4) 13 (3.1) 1.00 (ref) 12.23 115 (26.1) 103 (24.1) 1.01 (.45-2.28)				F = .027	
Never 161 (33.1) 169 (36.2) 1.00 (ref) Induced only 71 (14.6) 72 (15.4) 1.06 (.71-1.58) Miscarriage only 197 (40.4) 170 (36.4) 1.19 (.87-1.61) Both induced and miscarriage 58 (11.9) 56 (12.0) 1.02 (.66-1.58) Breastfeeding ^b 2 2 1.00 (ref) Ever 443 (91.0) 426 (91.4) 1.00 (ref) Never 444 (9.0) 40 (8.6) 1.49 (.55-4.39) Breastfeeding duration ^b - - - <12	Abortion				
Induced only /1 (14.6) /2 (15.4) 1.06 (./1-1.58) Miscarriage only 197 (40.4) 170 (36.4) 1.19 (.87-1.61) Both induced and miscarriage 58 (11.9) 56 (12.0) 1.02 (.66-1.58) Breastfeeding ^b 100 (ref) 1.00 (ref) Ever 443 (91.0) 426 (91.4) 1.00 (ref) Never 44 (9.0) 40 (8.6) 1.49 (.55-4.39) Breastfeeding duration ^b 115 (3.4) 13 (3.1) 1.00 (ref) 12-23 115 (26.1) 103 (24.1) 1.01 (.45-2.28)	Never	161 (33.1)	169 (36.2)	1.00 (ref)	
Miscarriage only 197 (40.4) 170 (36.4) 1.19 (.87-1.61) Both induced and miscarriage 58 (11.9) 56 (12.0) 1.02 (.66-1.58) Breastfeeding ^b Ever 443 (91.0) 426 (91.4) 1.00 (ref) Never 444 (9.0) 40 (8.6) 1.49 (.55-4.39) Breastfeeding duration ^b 15 (3.4) 13 (3.1) 1.00 (ref) 12-23 115 (26.1) 103 (24.1) 1.01 (.45-2.28)	Induced only	/1 (14.6)	72 (15.4)	1.06 (./1-1.58)	
Both induced and miscarriage 58 (11.9) 56 (12.0) 1.02 (.66-1.58) Breastfeeding ^b Ever 443 (91.0) 426 (91.4) 1.00 (ref) Never 444 (9.0) 40 (8.6) 1.49 (.55-4.39) Breastfeeding duration ^b	Miscarriage only	197 (40.4)	170 (36.4)	1.19 (.87-1.61)	
Breastfeeding ^b 443 (91.0) 426 (91.4) 1.00 (ref) Never 44 (9.0) 40 (8.6) 1.49 (.55-4.39) Breastfeeding duration ^b	Both induced and miscarriage	58 (11.9)	56 (12.0)	1.02 (.66-1.58)	
Ever 443 (91.0) 426 (91.4) 1.00 (ref) Never 44 (9.0) 40 (8.6) 1.49 (.55-4.39) Breastfeeding duration ^b	Breastfeeding ^D				
Never 44 (9.0) 40 (8.6) 1.49 (.55-4.39) Breastfeeding duration ^b	Ever	443 (91.0)	426 (91.4)	1.00 (ref)	
Breastfeeding duration ^b IS (3.4) IS (3.1) I.00 (ref) 12-23 115 (26.1) 103 (24.1) 1.01 (.45-2.28)	Never	44 (9.0)	40 (8.6)	1.49 (.55-4.39)	
<12 15 (3.4) 13 (3.1) 1.00 (ref) 12-23 115 (26.1) 103 (24.1) 1.01 (.45-2.28)	Breastfeeding duration ^b				
12-23 115 (26.1) 103 (24.1) 1.01 (.45-2.28)	<12	15 (3.4)	13 (3.1)	1.00 (ref)	
	12-23	115 (26.1)	103 (24.1)	1.01 (.45-2.28)	
≥24 311 (70.5) 311 (72.8) .95 (.42-2.10)	≥24	311 (70.5)	311 (72.8)	.95 (.42-2.10)	
Trend test $P = .71$	Trend test		. ,	P = .71	

 $^{\rm a}{\rm Adjusted}$ for age, first-degree family cancer history, income. $^{\rm b}{\rm additionally}$ adjusted for number of live births among parous women.

		Pre-menopau:	se		Post-menopau	se
	Cases	Controls		Cases	Controls	
Variables	N (%)	N (%)	OR (95% CI) ^a	N (%)	N (%)	OR (95% CI) ^a
Age at menarche						
≥ 3	241 (93.4)	239 (97.6)	1.00 (ref)	213 (97.7)	201 (96.6)	1.00 (ref)
< 3	17 (6.6)	6 (2.4)	2.66 (1.08-7.51)	5 (2.3)	7 (3.4)	.75 (.22-2.43)
P _{heterogeneity} =.05* Parity						
Ever	246 (94.6)	236 (95.9)	1.00 (ref)	204 (90.7)	194 (89.4)	1.00 (ref)
Never	14 (5.4)	10 (4.1)	1.66 (.68-4.33)	21 (9.3)	23 (10.6)	.98 (.50-1.88)
P _{heterogeneity} = .41* Number live births						
I	33 (13.1)	19 (8.1)	1.00 (ref)	39 (14.2)	20 (10.3)	1.00 (ref)
2	166 (65.9)	140 (59.3)	.74 (.39-1.36)	91 (44.6)	87 (44.8)	.71 (.36-1.35)
≥3	53 (21.0)	77 (32.6)	.42 (.2183)	84 (41.2)	87 (44.8)	.62 (.32-1.20)
Trend test			P = .003			P = .23
$P_{heterogeneity} = .15^*$						
Age at first live birth						
<25	140 (56.9)	162 (68.9)	1.00 (ref)	106 (52.0)	116 (60.1)	1.00 (ref)
25-29	85 (34.6)	59 (25.1)	1.67 (1.10-2.54)	67 (32.8)	57 (29.5)	1.29 (.82-2.04)
30-34	12 (4.9)	10 (4.3)	1.31 (.52-3.36)	16 (7.8)	11 (5.7)	1.54 (.67-3.69)
≥35	9 (3.7)	4 (1./)	2.05 (.60-8.25)	15 (7.4)	9 (4./)	1.53 (.55-4.43)
I rend test			P = .048			P = .21
$P_{heterogeneity} = .49^*$ Breastfeeding ^b						
Ever	242 (93.1)	232 (94.7)	1.00 (ref)	200 (88.9)	191 (87.6)	1.00 (ref)
Never	18 (6.9)	13 (5.3)	2.66 (.62-18.25)	25 (11.1)	27 (12.4)	.81 (.18-3.52)
P _{heterogeneity} = .39 Breastfeeding duration	b					
<12	9 (3.8)	5 (2.1)	1.00 (ref)	6 (3.0)	8 (4.2)	1.00 (ref)
12-23	63 (26.2)	55 (23.6)	.57 (.16-1.83)	52 (26.0)	48 (25.1)	1.88 (.59-6.31)
≥24	168 (70.0)	173 (74.2)	.51 (.15-1.62)	142 (71.0)	135 (70.7)	1.89 (.60-6.23)
Trend test			P = .44			P = .63
P _{heterogeneity} = .37* BMI						
<18.5 kg/m ²	27 (11.0)	27 (10.4)	1.00 (ref)	18 (8.0)	28 (12.9)	1.00 (ref)
18.5-22.9 kg/m ²	153 (62.2)	170 (65.6)	1.15 (.64-2.09)	130 (57.8)	132 (60.8)	1.66 (.87-3.25)
23-27.5 kg/m ²	59 (24.0)	59 (22.8)	1.05 (.54-2.05)	72 (32.0)	52 (24.0)	2.18 (1.08-4.49)
>27.5 kg/m ²	7 (2.8)	3 (1.2)	.45 (.09-1.83)	5 (2.2)	5 (2.3)	1.56 (.38-6.44)
Trend test		. ,	P = .40			P = .05

Table 3. Association between menstrual and reproductive factors and breast cancer stratified by menopausal status.

*P_{heterogeneity} = .04, Test for heterogeneity.

^aAdjusted for age, first-degree family cancer history, income.

^badditionally adjusted for number of live births among parous women.

related to anovulation, leading to reduced exposure to estrogen and progesterone, and thus, lower risk of breast cancer.²⁹ The more than 3-fold elevated odds ratio for overall breast cancer, and most subtypes of breast cancer, associated with sometimes irregular menstruation has not been previously reported and may be caused by recall bias. Of note, the confidence intervals for the OR associated with irregular menstruation are extremely wide due to how few women reported having the condition. Therefore, this result should be interpreted with caution.

Similarly, late age at menopause is a well-established risk factor for breast cancer. Our results show that women aged 50 or over at menopause had an increased risk for breast cancer overall and HER-2+ and a suggested elevated risk of luminal A breast cancer. Late menopause is associated with increased lifetime exposure to estrogen, which

Table 4. Association between menstrual and reproductive factors and breast cancer by intrinsic subtypes.

	Controls		Luminal A		Luminal B		HER 2-enriched		TNBC
Variables	N	Ν	OR (95% CI) ^a	Ν	OR (95% CI) ^a	Ν	OR (95% CI) ^a	Ν	OR (95% CI) ^a
Age at menarche									
≥13	443	66	1.00 (ref)	7	1.00 (ref)	102	1.00 (ref)	41	1.00 (ref)
< 3	13	6	3.06 (1.04-8.16)	208	1.14 (.42-2.84)	6	1.93 (.66-5.06)	3	2.45 (.54-8.25)
Pheterogeneity = $.09^*$			· · · · · ·		(· · · · ·
Menopause									
No	246	42	1.00 (ref)	129	1.00 (ref)	51	1.00 (ref)	21	1.00 (ref)
Yes	218	32	.55 (.26-1.14)	88	.64 (.40-1.05)	58	1.37 (.74-2.54)	25	1.44 (.58-3.58)
Pheterogeneity = $.09^*$			(,		(/		(<i>'</i>		(/
Age at menopause									
<50	137	14	1.00 (ref)	50	1.00 (ref)	28	1.0 (ref)	14	1.00 (ref)
≥50	81	18	1.99 (.90-4.51)	38	1.17 (.69-1.98)	30	2.19 (1.14-4.23)	11	1.19 (.48-2.89)
Pheterogeneity = $.04^*$			(,		(/		· · · · · ·		(/
Regularity of menstrual cycle									
Regular	324	58	1.00 (ref)	167	1.00 (ref)	84	1.00 (ref)	32	1.00 (ref)
Irregular	133	13	.54 (.27-1.00)	32	.44 (.2867)	16	.46 (.2580)	9	.68 (.30-1.43)
Sometimes	10	4	2.62 (.68-8.50)	17	3.51 (1.57-8.24)	9	4.32 (1.59-11.81)	5	6.30 (1.77-20.89)
Length of menstrual cycle					(,		(,		(
<26 days	48	П	1.00 (ref)	38	1.00 (ref)	24	1.00 (ref)	7	1.00 (ref)
26-30 days	205	32	.69 (.33-1.55)	99	.64 (.39-1.06)	49	.49 (.2790)	21	.71 (.30-1.92)
>30 days	71	14	.80 (.33-1.98)	28	.49 (.2690)	П	.28 (.1263)	4	.36 (.09-1.28)
Trend test			P = .82		P = .03		P = .003		P = .12
Pheterogeneity = $.002^*$									
Parity									
Ever	433	72	1.00 (ref)	196	1.00 (ref)	104	1.00 (ref)	41	1.00 (ref)
Never	33	3	.62 (.14-1.89)	20	1.57 (.84-2.87)	6	.85 (.30-2.03)	5	1.79 (.56-4.85)
Pheterogeneity = $.33^*$		•		_•		-		•	
Number live births									
1	39	10	1 00 (ref)	28	1 00 (ref)	8	1 00 (ref)	9	1 00 (ref)
2	229	39	.70 (.33-1.58)	117	.73 (.42-1.26)	59	1.24 (.57-3.03)	18	.37 (.1694)
_ ≥3	165	23	.52 (.23-1.23)	51	.43 (.2479)	37	1.08 (.48-2.67)	14	.34 (.1489)
Trend test			P = .14		P = .002		P = .77		P = .12
Pheterogeneity = $.002^*$									
Age at first live birth ^b									
<25	279	35	1.00 (ref)	109	1.00 (ref)	61	1.00 (ref)	24	1.00 (ref)
25-29	118	28	1.91 (1.09-3.34)	63	1.38 (.93-2.04)	33	1.31 (.79-2.15)	13	1.25 (.58-2.60)
30-34	21	4	1.43 (.38-4.34)	15	1.58 (.73-3.33)	5	1.24 (.39-3.34)	1	.34 (.02-2.00)
>35	13	5	2.41 (.62-8.51)		1.37 (.51-3.58)	5	2.10 (.59-6.79)	3	1.36 (.25-5.88)
Trend test		•	P = .045	·	P = .13	•	P = .17	•	P = .91
Pheterogeneity = $.01^*$									
Abortion									
Never	168	23	1.00 (ref)	80	1.00 (ref)	32	1.00 (ref)	14	1.00 (ref)
Induced only	72	15	1.58 (.76-3.23)	30	.90 (.53-1.48)	14	1.07 (.52-2.11)	4	.65 (.18-1.91)
Miscarriage only	171	30	1.26 (.70-2.30)	78	.93 (.63-1.36)	48	1.51 (.91-2.52)	24	1.70 (.85-3.53)
Both induced and miscarriage	56	7	.91 (.34-2.17)	28	.98 (.56-1.66)	16	1.45 (.71-2.88)	4	.85 (.23-2.53)
Breastfeeding ^b		-						-	(
Ever	426	73	1.00 (ref)	192	1.00 (ref)	101	1.00 (ref)	39	1.00 (ref)
Never	40	2	-	24	1.48 (.41-5.05)	9	2.68 (.67-9.70)	7	3.10 (.43-14.91)
Pheterogeneity = 0.5^*		-				•		•	
Breastfeeding duration ^b									
<12	13	5	1.00 (ref)	5	1.00 (ref)	3	1.00 (ref)	2	1.00 (ref)
12-23	103	22	.66 (.21-2.29)	45	1.19 (.51-4.62)	25	1.02 (.29-4.79)	9	.63 (.13-4.66)
								•	

(continued)

	Cont	rols	Luminal A		Luminal B		HER 2-enriche	d	TNBC
Variables	N	Ν	OR (95% CI) ^a	Ν	OR (95% CI) ^a	Ν	OR (95% CI) ^a	Ν	OR (95% CI) ^a
≥24 Trend test	311	45	.41 (.13-1.39) P = .06	142	I.42 (.51-4.62) P = .36	72	.93 (.27-4.26) P = .73	28	.76 (.16-5.58) P = .89

Table 4. (continued)

*P_{heterogeneity} = .30.

aTest for heterogeneity of trend; P value across four molecular subtypes.

^aAdjusted for age, first-degree family cancer history, income.

^badditionally adjusted for the number of live births among parous women.

may account for the increased risk of breast cancer.³⁰ The lack of significance for luminal A breast cancer is likely due to the small sample size.

Our findings on reduced numbers of live births and late age at first live birth being associated with an increased risk of breast cancer were consistent with results of previous studies,³¹⁻³⁵ including those conducted in Vietnamese women.^{36,37} Our study, for the first time, showed that these associations varied by tumor subtype among Vietnamese women. Specifically, women with more than two children had a decreased risk of both luminal B and TNBC subtypes, and a suggested decreased risk of luminal A breast cancer, compared to women with one child. However, the number of live births was unrelated to HER 2+ breast cancer. These results support a different etiology for breast cancer subtypes, which warrants further investigation.

Our finding of a null association for miscarriage and abortion with breast cancer risk was consistent with a 2015 meta-analysis that showed no evidence from prospective studies on an association between breast cancer risk and abortion, including both induced and spontaneous abortion.⁸

We did not find that the length of time breastfeeding was significantly associated with breast cancer overall and by subtypes in our study, which is inconsistent with some of the earlier findings.^{38,39} It should be noted that 96.6% of cases and 96.9% of controls in our study have had breastfeeding experience, most for longer than 12 months. Thus, our study has low statistical power to investigate the influence of no or short-term breastfeeding on breast cancer risk.

The large sample size, high participation rate, standardized data collection, and availability of breast cancer subtype information are significant strengths of our study. However, our study also has several limitations. First, our study was hospital-based; therefore, selection bias cannot be excluded. Nevertheless, the Vietnam National Cancer Hospital and the Hanoi Oncology Hospital are the leading hospitals treating most breast cancer patients in Northern Vietnam. Because most Vietnamese have government-provided health insurance, systematic selection bias is minimized. In addition, we have adjusted for education and family income in our analysis to reduce selection bias further. Second, like almost all previous studies, information regarding menstrual and reproductive factors is self-reported. Misclassification is unavoidable and may introduce a biased estimation for the associations between menstrual/reproductive factors and breast cancer. Because our study is a retrospective by design, contrary to prospective studies, the bias may be differential. Third, most controls (95.9%) were recruited from female relatives or friends of cancer patients other than those treated for breast cancer at the Vietnam National Cancer Hospital. Therefore, they may not be a representative sample of Vietnam's general population. This may be why the family history of cancer among controls was similar to that of cases in our study. This raises a potential concern that the association estimation derived from our research may be somewhat underestimated or overestimated.

Conclusion

In summary, in this first large case-control study investigating breast cancer risk factors by tumor subtype in Vietnam, we found that menstrual and reproductive factors played an important role in breast cancer etiology, particularly among premenopausal women and for hormonal positive breast cancer subtypes. Therefore, our findings are imperative for developing breast cancer prevention strategies in Vietnam, particularly given the recent changing trends in menstrual and reproductive patterns in the younger generation of Vietnamese women.

Abbreviations

BMI	body mass index
CI	confidence interval
ER	estrogen receptor
IA	induced abortion
HER-2	human epidermal growth
	factor receptor 2
OR	odds ratio
PRprogesterone receptorSA	progesterone
	receptorSAspontaneous
	abortion
SD	standard deviation
TNBC	triple-negative breast cancer

Acknowledgments

The authors would like to give special thanks to the participants and the research staff members of this project, without whom this study would not have been possible. We also thank Dr. Mary Shannon Byers and Ms Rachel Mullen for their assistance in editing this manuscript.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by NIH/NCI Grant # P20 CA210300 and OISE-19-66185-1 (PIs: Xiao-Ou Shu and Thuan V. Tran). Sang Nguyen was supported by a VECD Global Health Fellowship, funded by the National Cancer Institute (NCI) and the Fogarty International Center (FIC) of the NIH (D43 TW009337) and Ingram Cancer Professorship Fund (to Dr. Shu).

Authors' Contributions

Conception and design: O. T. Bui, H.TT. Tran, X. O. Shu, Development of methodology: O. T. Bui, X. O. Shu, Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): O. T. Bui, H. TT. Tran, S. M. Nguyen, T.V. Dao, Q. V. Bui, A. T. Pham, M. J. Shrubsole, Q. Cai, F. Ye, W. Zheng, H. N. Luu, T. V. Tran, X. O. Shu, Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): O. T. Bui, S. M. Nguyen, X. O. Shu, Writing, review, and or revision of the manuscript: O. T. Bui, S. M. Nguyen, H.TT. Tran, X. O. Shu, Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): O. T. Bui, H. T. T. Tran, S. M. Nguyen, T. V. Dao, Q. V. Bui, A. T. Pham, M. J. Shrubsole, Q. Cai, F. Ye, W. Zheng, H. N. Luu, T. V. Tran, X. O. Shu, Study supervision: H. T. T. Tran, T. V. Tran, X. O. Shu

Ethical Approval

The protocol of this study was approved by the Vietnam National Cancer Institute and Vanderbilt University Medical Center.

Informed Consent

All patients provided written informed consent prior to enrollment in the study.

ORCID iDs

Oanh Thi Bui [©] https://orcid.org/0000-0002-0850-759X Sang Minh Nguyen [©] https://orcid.org/0000-0002-4338-8477 Tu Van Dao [©] https://orcid.org/0000-0001-6858-8347 Anh Tuan Pham [©] https://orcid.org/0000-0002-5961-1725 Hung Nguyen Luu [®] https://orcid.org/0000-0002-2172-1849 Thuan Van Tran [®] https://orcid.org/0000-0002-5839-0895

Supplemental Material

Supplemental material for this article is available online.

References

- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3): 209-249. doi:10.3322/caac.21660
- Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world*Breast Cancer Dove Med Press.* 11;2019:151-164. 10.2147/BCTT. S176070
- Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer—Epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. *Cancers*. 2021;13(17):4287. doi: 10.3390/cancers13174287
- Inumaru LE, Irineu Gomes Duarte Quintanilha M, Da Silveira ÉA, Veloso Naves MM. Risk and protective factors for breast cancer in Midwest of Brazil. *J Environ Public Health*. 2012; 2012:356851. doi:10.1155/2012/356851
- Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. *Lancet Oncol.* 2012; 13(11):1141-1151. doi:10.1016/S1470-2045(12)70425-4
- Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: A meta-analysis of epidemiological studies. *Breast Cancer Res.* 2006;8(4):R43. doi:10.1186/bcr1525
- Lambertini M, Santoro L, Del Mastro L, et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. *Cancer Treat Rev.* 2016;49:65-76. doi:10. 1016/j.ctrv.2016.07.006
- Guo J, Huang Y, Yang L, et al. Association between abortion and breast cancer: An updated systematic review and meta-analysis based on prospective studies. *Cancer Causes Control*. 2015; 26(6):811-819. doi:10.1007/s10552-015-0536-1
- Holm J, Eriksson L, Ploner A, et al. Assessment of breast cancer risk factors reveals subtype heterogeneity. *Cancer Res.* 2017; 77(13):3708-3717. doi:10.1158/0008-5472.CAN-16-2574
- Nguyen J, Le QH, Duong BH, et al. A matched case-control study of risk factors for breast cancer risk in vietnam. *International Journal of Breast Cancer*. 2016;2016:1-7. doi:10.1155/ 2016/7164623
- Trieu PDY, Mello-Thoms C, Peat JK, Do TD, Brennan PC. Risk factors of female breast cancer in vietnam: A case-control study. *Cancer Res Treat*. 2017;49(4):990-1000. doi:10.4143/crt.2016. 488
- Nguyen SM, Tran HTT, Nguyen LM, et al. Association of fruit, vegetable, and animal food intakes with breast cancer risk overall and by molecular subtype among vietnamese women.

Cancer Epidemiol Biomarkers Prev. 2022;31(5):1026-1035. doi:10.1158/1055-9965.EPI-21-1085

- Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inf.* 2019;95:103208. doi:10.1016/j.jbi.2019. 103208
- Devi CRB, Tang TS, Corbex M. Incidence and risk factors for breast cancer subtypes in three distinct South-East Asian ethnic groups: Chinese, Malay and natives of Sarawak, Malaysia. *Int J Cancer*. 2012;131(12):2869-2877. doi:10.1002/ijc.27527
- Xing P, Li J, Jin F. A case–control study of reproductive factors associated with subtypes of breast cancer in Northeast China. *Med Oncol.* 2010;27(3):926-931. doi:10.1007/s12032-009-9308-7
- 16. Liabsuetrakul T. Southern soil-transmitted helminths and maternal health working group. is international or asian criteriabased body mass index associated with maternal anaemia, low birthweight, and preterm births among thai population? an observational study. *J health popul Nutr*. 2011;29(3):218-228. doi:10.3329/jhpn.v29i3.7869
- von Elm E, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (strobe) statement: Guidelines for reporting observational studies. *BMJ*. 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782
- Nguyen SM, Nguyen QT, Nguyen LM, et al. Delay in the diagnosis and treatment of breast cancer in Vietnam. *Cancer Med.* 2021;10(21):7683-7691. doi:10.1002/cam4.4244
- Gao YT, Shu XO, Dai Q, et al. Association of menstrual and reproductive factors with breast cancer risk: Results from the shanghai breast cancer study. *Int J Cancer*. 2000;87(2):295-300.
- Liu YT, Gao CM, Ding JH, et al. Physiological, reproductive factors and breast cancer risk in Jiangsu province of China. *Asian Pac J Cancer Prev.* 2011;12(3):787-790.
- de Almeida GS, Almeida LAL, Araujo GMR, Weller M. Reproductive risk factors differ among breast cancer patients and controls in a public hospital of paraiba, Northeast Brazil. *Asian Pac J Cancer Prev APJCP*. 2015;16(7):2959-2965. doi:10. 7314/APJCP.2015.16.7.2959
- Winters S, Martin C, Murphy D, Shokar NK. Breast cancer epidemiology, prevention, and screening. In *Progress in molecular biology and translational science*, Vol 151. Elsevier; 2017:1-32. doi:10.1016/bs.pmbts.2017.07.002
- Msolly A, Gharbi O, Ben Ahmed S. Impact of menstrual and reproductive factors on breast cancer risk in Tunisia: A case– control study. *Med Oncol.* 2013;30(1). doi:10.1007/s12032-013-0480-4
- Xu YL, Sun Q, Shan GL, et al. A case-control study on risk factors of breast cancer in China. *Arch Med Sci.* 2012;8(2): 303-309. doi:10.5114/aoms.2012.28558
- Li H, Sun X, Miller E, et al. BMI, reproductive factors, and breast cancer molecular subtypes: A case-control study and meta-analysis. *J Epidemiol*. 2017;27(4):143-151. doi:10.1016/j. je.2016.05.002

- Sisti JS, Collins LC, Beck AH, Tamimi RM, Rosner BA, Eliassen AH. Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies: Reproductive factors and molecular subtypes of breast cancer. *Int J Cancer*. 2016;138(10):2346-2356. doi:10.1002/ijc. 29968
- Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC. Do regular ovulatory cycles increase breast cancer risk? *Cancer*. 1985;56(5):1206-1208.
- Pike MC, Henderson BE, Casagrande JT, Rosario I, Gray GE. Oral contraceptive use and early abortion as risk factors for breast cancer in young women. *Br J Cancer*. 1981;43(1):72-76. doi:10.1038/bjc.1981.10
- Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC. Do regular ovulatory cycles increase breast cancer risk? *Cancer*. 1985;56(5):1206-1208.
- 30. Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. *Breast Cancer Res.* 2003;5(5):239. doi:10.1186/bcr628
- Li H, Sun X, Miller E, et al. BMI, reproductive factors, and breast cancer molecular subtypes: A case-control study and meta-analysis. *J Epidemiol*. 2017;27(4):143-151. doi:10.1016/j. je.2016.05.002
- Akbari A, Razzaghi Z, Homaee F, Khayamzadeh M, Movahedi M, Akbari ME. Parity and breastfeeding are preventive measures against breast cancer in Iranian women. *Breast Cancer*. 2011;18(1):51-55. doi:10.1007/s12282-010-0203-z
- Pizot C, Boniol M, Mullie P, et al. Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies. *Eur J Cancer*. 2016;52:138-154. doi:10. 1016/j.ejca.2015.10.063
- Wu JQ, Li YY, Ren JC, Zhao R, Zhou Y, Gao ES. Induced abortion and breast cancer: results from a population-based case control study in China. *Asian Pac J Cancer Prev APJCP*. 2014; 15(8):3635-3640. doi:10.7314/APJCP.2014.15.8.3635
- 35. Galukande M, Wabinga H, Mirembe F, Karamagi C, Asea A. Breast cancer risk factors among ugandan women at a tertiary hospital: A case-control study. *Oncology*. 2016;90(6):356-362. doi:10.1159/000445379
- Nguyen J, Le QH, Duong BH, et al. A matched case-control study of risk factors for breast cancer risk in vietnam. *International Journal of Breast Cancer*. 2016;2016:1-7. doi:10.1155/ 2016/7164623
- Trieu PDY, Mello-Thoms C, Peat JK, Do TD, Brennan PC. Risk factors of female breast cancer in vietnam: A case-control study. *Cancer Res Treat*. 2017;49(4):990-1000. doi:10.4143/crt.2016. 488
- Gao YT, Shu XO, Dai Q, et al. Association of menstrual and reproductive factors with breast cancer risk: Results from the shanghai breast cancer study. *Int J Cancer.* 2000;87(2): 295-300.
- Lodha RS, Nandeshwar S, Pal DK, et al. Risk factors for breast cancer among women in Bhopal urban agglomerate: A casecontrol study. *Asian Pac J Cancer Prev.* 2011;12(8):2111-2115.